Origin Survival Comments Breast Median 33 months [21] Following diagnosis of bone metastases only Overall survival 30 months 10.6 months 27.3 months [26] ER+/PR+ Triple negative Bone metastases only Prostate…
Primary tumor (T) TX: Primary tumor cannot be assessed T0: No evidence of primary tumor T1: Tumor ≤7 cm in greatest dimension, limited to the kidney T1a: Tumor ≤4 cm…
Prostate Lung Breast Study years 1999–2007 1999–2010 1999–2007 Patients 23,087 29,720 35,912 Mets at diagnosis 569 (3 %) 254 (0.9 %) 178 (0.5 %) Developed mets 2578 (11.5 %)…
© Springer Science+Business Media New York 2016R. Lor Randall (ed.)Metastatic Bone Disease10.1007/978-1-4614-5662-9_20 20. Questions to Ask Your Medical Oncology Colleagues Noah Federman1, Amanda Loftin2 and Nicholas M. Bernthal2 (1) Pediatrics, Joint Appointment in Orthopaedics, UCLA David Geffen School…
Fig. 19.1 Abbreviated ACA/AHA Peri0op evaluation schema [3]. MACE major adverse cardiac risk event, GDMT guideline directed medical therapy, MET metabolic equivalent The American College of Surgeons (ACS) developed a…
Fig. 15.1 A modification of the World Health Organization ladder of pain management showing contemporary pain management techniques. From Fine PG. The evolving and important role of anesthesiology in palliative…
© Springer Science+Business Media New York 2016R. Lor Randall (ed.)Metastatic Bone Disease10.1007/978-1-4614-5662-9_14 14. Psychosocial Considerations for Patients with Metastatic Bone Disease Amy Horyna1 (1) Patient and Family Support, Huntsman Cancer Hospital, Salt Lake City, UT,…
© Springer Science+Business Media New York 2016R. Lor Randall (ed.)Metastatic Bone Disease10.1007/978-1-4614-5662-9_13 13. Biotargeting in Metastatic Bone Disease Anna R. Cooper1 , Wakenda Tyler2 and Emily E. Carmody1 (1) Orthopaedics and Rehabilitation, University of Rochester Medical Center, 601 Elmwood Ave.,…
Stage Tumor (T) Node (N) Metastatic (M) Stage 0 Tis (carcinoma in situ) N0 M0 Stage IA T1 (≤20 mm) N0 M0 Stage IB T0 or T1 (≤20 mm) N1mi…
